Many studies have been done using Mitomycin-C as antimetabolites. However the results are variable. Mitomycin-C is an alkylating agent derived from Streptomyces caespitosus. Few studies regarding the efficacy of this drug have been undertaken and further studies are needed to determine and confirm the efficacy of this drug. The present study was conducted to evaluate the success rate and to compare the results of endoscopic DCR with and without intraoperative Mitomycin-C. The present study was planned in the Department of ENT in NMCH Patna from July 2018 to Dec 2018.The 40 patients presented with symptoms and signs suggestive of chronic dacryocystitis secondary to distal nasolacrimal duct blockage were enrolled in the present study. The information generated from the present study concludes that endoscopic endonasal dacryocystorhinostomy is the surgery of choice for primary acquired nasolacrimal duct obstruction. Intraoperative mitomycin C prevents narrowing of ostium. Topical mitomycin C is safer with no local adverse effects. Use of adjuvant mitomycin C enhances the success rate of surgery with less chances of recurrence.